Posts Tagged ‘Depression’

Gluten sensitivity without celiac disease in the elderly: is there a concern?

Monday, July 19th, 2010

Scandinavian Journal of GastroenterologyOften tests shows anti-gliadin antibodies (AGA; gliadin is the immunoreactive component of gluten) in the absence of celiac disease but with various autoimmune conditions representing the non-celiac manifestations of gluten sensitivity. The authors of a study just published in the Scandinavian Journal of Gastroenterology explore this issue for the elderly.

“…data suggest that AGA positivity [without celiac disease] might be related to distinct disease entities such as allergy and gluten ataxia (loss of muscular coordination with unsteady movements and gait). Our aim here is to explore the clinical relevance of positive AGA in the elderly population.”

The authors correlated positive lab tests for gluten sensitivity with the incidence of depression and rheumatoid arthritis in 2815 individuals aged 52–74 years. What did their data show?

Rheumatoid arthritis and depression were found significantly more often in AGA-positives than controls. The significance remained even when tTGA-positive and known celiac disease cases were excluded.”

Don’t forget that anti-gliadin antibody tests are not an absolute screen for gluten (or any other food) sensitivity because there are a number of factors that can suppress the expression of antibodies at the time of specimen collection. However, this study shows that if an elderly person is suffering from depression or rheumatoid arthritis the possibility of gluten sensitivity should be investigated.

Bookmark and Share

Gluten-free diet can improve depression and behavioral problems in adolescents

Friday, May 28th, 2010

BMC PsychiatryAs the authors of this study published in the journal BMC Psychiatry observe:

“Coeliac disease in adolescents has been associated with an increased prevalence of depressive and disruptive behavioural disorders, particularly in the phase before diet treatment.”

We are equally concerned with the ‘non-celiac’ aspects of gluten sensitivity. Gluten related inflammation in the brain can manifest as a host of cognitive, emotional and neurodegenerative disorders in the absence of intestinal manifestations. This is often referred to as “silent celiac disease”:

“Coeliac disease is an under-diagnosed autoimmune type of gastrointestinal disorder resulting from gluten ingestion in genetically susceptible individuals. Non-specific symptoms such as fatigue and dyspepsia are common, but the disease may also be clinically silent.”

They further note that:

“”Depressive symptoms and disorders are common among adult patients with coeliac disease, and depressive and disruptive behavioural disorders are highly common also among adolescents, particularly in the phase before diet treatment. Recently 73% of patients with untreated coeliac disease – but only 7% of patients adhering to a gluten-free diet – were reported to have cerebral blood flow abnormalities similar to those among patients with depressive disorders.”

Their data revealed abnormalities in tryptophan assimilation (tryptophan is the amino acid precursor to serotonin) and prolactin levels in adolescents with celiac disease and depression prior to treatment. Consequently…

A significant decrease in psychiatric symptoms was found at 3 months on a gluten-free diet compared to patients’ baseline condition, coinciding with significantly decreased coeliac disease activity…”

They also make a fascinating observation that links gluten sensitivity, inflammation, and the serotonergic aspect of depression unrelated to malabsorption:

“…increased production of interferon-γ (IFN-γ), known to be the predominant cytokine produced by gluten-specific T-cells in active coeliac disease, can suppress serotonin function both directly and indirectly by enhancing tryptophan and serotonin turnover…even without malabsorption.”

To diagnose gluten sensitivity in the absence of celiac disease the gluten gene sensitivity test is the most reliable method for a number of reasons.

Bookmark and Share

Vitamin D and depression in older men and women

Sunday, May 16th, 2010

Journal of Clinical Endocrinology & MetabolismA study recently published in the Journal of Clinical Endocrinology & Metabolism adds more evidence to the importance of maintaining optimum vitamin D levels by investigating the link between suboptimal vitamin D and depression.

“We examined the relationship between 25-hydroxyvitamin D [25(OH)D] and depressive symptoms over a 6-yr follow-up in a sample of older adults.”

The authors measured 25(OH)D in 531 women and 423 men aged 65 and older while assessing them for depressive symptoms with the Center for Epidemiological Studies-Depression Scale (CES-D)over a 6 year period (and adjusted for relevant biomarkers and variables). When they crunched the numbers this is what emerged:

Women with 25(OH)D less than 50 nmol/liter compared with those with higher levels experienced increases in CES-D scores [and]…significantly higher risk of developing depressive mood over the follow-up. In parallel models, men with 25(OH)D less than 50 nmol/liter compared with those with higher levels experienced increases in CES-D scores [and]…tended to have higher risk of developing depressed mood.”

There are a number of ways that suboptimal vitamin D can contribute to depression (some of which you can read about among these posts). The authors did not investigate the causal mechanisms but settled with this conclusion:

“Our findings suggest that hypovitaminosis D is a risk factor for the development of depressive symptoms in older persons.”

Bookmark and Share

Iron supplementation can cause a zinc deficiency—implications for anger and depression

Friday, May 7th, 2010

British Journal of NutritionEven borderline anemia due to mild iron deficiency has profound effects. But as this study recently published in the British Journal of Nutrition reveals, care must be taken to avoid creating a functional zinc deficiency even when iron supplementation is necessary. The authors begin by observing…

“Interventions to combat mild Fe deficiency in women of childbearing age may affect Zn nutriture.”

Three groups of subjects with low iron were randomly assigned to one of three groups: dietary advice, a daily iron supplement and placebo. Their data showed that serum zinc increased in the dietary advice group (who ate more meat) and the placebo group. In the iron supplement group zinc decreased, leading to their conclusion:

“Zn status was not improved compared with placebo by an Fe-based dietary intervention. However, a daily moderate-dose Fe supplement with meals appeared to lower Zn status in these young adult women.”

European Journal of Clinical NutritionAmong its many functions, zinc is involved in neurotransmitter production and the regulation of mood. This important study recently published in the European Journal of Clinical Nutrition begins with the observation…

“The relation of zinc (Zn) nutriture to brain development and function has been elucidated. The purpose of this study is to examine whether Zn supplementation improves mood states in young women.”

The authors used a double-blind, randomized and placebo-controlled procedure to correlate psychological measures, somatic symptoms and serum zinc in two groups who took either a multivitamin or a multivitamin with zinc daily for 10 weeks. What did their data reveal?

Women who took MV and Zn showed a significant reduction in anger–hostility score and depression–dejection score in the Profile of Moods State (POMS) and a significant increase in serum Zn concentration, whereas women who took only MV did not.”

The authors summarized their findings by concluding:

“Our results suggest that Zn supplementation may be effective in reducing anger and depression.”

It’s easy to see the strong biological momentum to feeling angry and/or depressed around menstruation? Iron is a necessary co-factor for both serotonin and dopamine. Supplementing iron can reduce zinc status, also an important mood-regulating co-factor. Even without adding the hormonal component it’s clear why so many women need help with this.

Bookmark and Share

Side effects of antidepressants are grossly underrecognized by psychiatrists

Sunday, April 25th, 2010

Journal of Clinical Psychiatry 2A study just published in The Journal of Clinical Psychiatry brings to light the extent to which the side effects of common antidepressant medications are not recognized or reported by psychiatrists. The authors state:

“Despite the clinical importance of detecting side effects, few studies have examined the adequacy of their detection and documentation by clinicians.”

The authors set out to compare the side effects recorded in the charts of three hundred depressed outpatients undergoing treatment with their own report on a side effects checklist. These were rated according to frequency and the degree of trouble they caused. Their data described a stunning difference:

The mean number of side effects reported by the patients on the TSES (Toronto Side Effects Scale) was 20 times higher than the number recorded by the psychiatrists.”

Their conclusion is disturbing:

Psychiatrists may not be aware of most side effects experienced by psychiatric outpatients receiving ongoing pharmacologic treatment for depression.”

Friends, consider the functional medicine approach that objectively evaluates the underlying causal physiology of depression and applies evidence-based interventions on an individual basis that are free of side effects.

Bookmark and Share

Neurotransmitter GABA important for major depression

Monday, April 5th, 2010

Biological PsychiatryThis paper just published in the journal Biological Psychiatry reports on valuable finding that is important for anyone suffering from or treating major depression needs to know: the neurotransmitter GABA can play a significant role in the biological component of major depression. GABA is the most abundant inhibitory neurotransmitter in our bodies. The authors note that

“Several lines of evidence suggest that major depressive disorder is associated with deficits in γ-aminobutyric acid (GABA) inhibitory neurotransmission.”

In their study they used transcranial magnetic stimulation to measure the integrity of GABA function in

“medicated patients with treatment resistant major depressive disorder (TRD), unmedicated patients with major depressive disorder, and medicated euthymic [normal mood] patients with a history of major depressive disorder and compare them with healthy subjects.”

Their compelling findings were that

All major depressive disorder patient groups demonstrated significant cortical silent period deficits [GABA(B) receptor-mediated inhibitory neurotransmission] compared with healthy subjects.” Interestingly, “only TRD [treatment resistant depression] patients demonstrated significant deficits in short-interval cortical inhibition [GABA(A) receptor-mediated inhibitory neurotransmission] compared with healthy subjects, medicated euthymic major depressive disorder patients, and unmedicated major depressive disorder patients.”

I’m sure readers know that there is much more to the story of major depression than one neurotransmitter. But this is a welcome study for functional medicine practitioners who have seen empirically positive results since we have excellent resources for physiologically supporting improved GABA function. They also noted another finding important for functional medicine doctors and neurotherapists who treat additional biological causes of depression (metabolic, inflammatory, electrical, etc):

“TRD patients also demonstrated a significantly greater resting motor threshold compared with all other clinical subgroups and healthy subjects, suggesting that TRD was also associated with hypoexcitability of the frontal cortex.”

The authors state in conclusion:

“Our findings suggest that GABA(B) neurophysiological deficits are closely related to pathophysiology of major depressive disorder. Our findings also suggest that more severe illness is selectively associated with GABA(A) receptor-mediated inhibitory deficits.”

By the way, four years earlier to the day there was a paper published in the same journal that concluded:

“This study provides evidence of reduced GABAergic [GABA function] tone and motor threshold asymmetry in patients with major depression.”

For an easy reading description on how this investigative approach can help personalize the treatment of depression and more on why GABA is important see this article.

Bookmark and Share

Depression involves brain inflammation

Thursday, April 1st, 2010

Biological PsychiatryNot to oversimplify since depression can have multiple contributing causes, but there have been many studies published about brain inflammation as an important component of major and minor depression. An illuminating paper published in the latest volume of the journal Biological Psychiatry undertakes an extensive analysis of accumulated scientific evidence. The authors begin by noting:

“Major depression occurs in 4.4% to 20% of the general population. Studies suggest that major depression is accompanied by immune dysregulation and activation of the inflammatory response system (IRS). Our objective was to quantitatively summarize the data on concentrations of specific cytokines in patients diagnosed with a major depressive episode and controls.”

Cytokines are, among other things, signalling molecules that regulate immune system function. This has great practical significance because there is an evidence-based approach in functional medicine to analyzing and treating cytokine imbalances. The authors evaluated 24 studies that included eight different cytokines. Here’s what their data showed:

“This meta-analysis reports significantly higher concentrations of the proinflammatory cytokines TNF-α and IL-6 in depressed subjects compared with control subjects…this meta-analytic result strengthens evidence that depression is accompanied by activation of the IRS.”

You may enjoy the interesting comment on this study just published in Journal Watch.

PharmacopsychiatryAlthough this is a valuable study it’s important to keep a broad perspective. Here’s another paper published not long ago in the journal Pharmacopsychiatry, one among many others on cytokines and depression. It documents cases of brain inflammation with a different cytokine pattern. This paper is also interesting for the therapeutic comparison of Prozac and electroacupuncture:

“An increase in inflammatory response and an imbalance between T-helper (Th) 1 and 2 functions have been implicated in major depression. The aims of the present study were to 1) study the relationship between pro- and anti-inflammatory cytokines and between Th1 and Th2 produced cytokines in depressed patients and 2) evaluate and compare the effect of treatments with electroacupuncture (EA) and fluoxetine on these cytokines.”

Th1 and Th2 are the two primary poles of immune system function, cell-mediated and humoral (antibody). Imbalances result in immune dysregulation. Fluoxetine is Prozac. (The inclusion of electroacupuncture might tip you off that this study was done in Germany.) Their data tells a fascinating story:

Increased proinflammatory cytokine interleukin (IL)-1β and decreased anti-inflammatory cytokine IL-10 were found in the depressed patients. By contrast, Th1 produced proinflammatory cytokines, tumor necrosis factor (TNF)-α and interferon (IFN)-γ were decreased, and Th2 produced cytokine IL-4 was significantly increased in depressed patients…Both acupuncture and fluoxetine treatments, but not the placebo, reduced IL-1β concentrations in responders. However, only acupuncture attenuated TNF-α concentration and INF-γ/IL-4 ratio towards the control level.”

How interesting that what we call a peripheral sensory nervous system modality (stimulation of the brain through the peripheral sensory nerves, in this case with electroacupuncture) reduced inflammation and TNF-α. This corresponds exactly with my clinical experience employing these modalities for a range of conditions including autoimmune disorders, and explains part of why patients feel so much better after a treatment. Their conclusion is worth noting:

These results suggest that an imbalance between the pro- and anti-inflammatory cytokines (IL-1 and IL-10), and between Th1 and Th2 cytokines (INF-γ or TNF-α and IL-4) occurred in untreated depressed patients. Both EA and fluoxetine had an anti-inflammatory effect by reducing IL-1β. EA treatment also restored the balance between Th1 and Th2 systems by increasing TNF-α and decreasing IL-4.”

Thus depression involves inflammation, but the cytokine expression can vary.

Journal of Psychiatric PracticeThis topic is multifaceted and a proper synopsis of the functional approach to depression is too long for this forum, but here’s one more paper to keep the horizon open. This study published not long ago in the Journal of Psychiatric Practice investigates the role of low testosterone in depression.

“Studies suggest that testosterone (TT) replacement may have an antidepressant effect in depressed patients…The objective of this study was to explore the effect of TT administration on depression using both a systematic review of the literature and a meta-analysis.”

What did the data show?

“Meta-analysis of the data from these seven studies showed a significant positive effect of TT therapy on…depressed patients when compared with placebo. Subgroup analysis also showed a significant response in the subpopulations with hypogonadism…”

This certainly confirms expectations considering the population of testosterone receptors in the brain and their density in the frontal lobe. Hypogonadism means that the testicles are producing too little testosterone in response to stimulation by luteinizing hormone (LH). This validates my common sense practice of always including biologically active free fraction testosterone and LH in workups for male depression. Note: testosterone replacement, especially by a transdermal route (gel, patch, cream) can give a good initial result but end up back-firing. This is a topic for another post. For now just remember there is a better way.

Bookmark and Share

Even mild anemia has a big impact

Sunday, March 21st, 2010

Because anemia degrades the ability of the blood to carry oxygen to every cell in the body it has a profound and global affect on function, especially for the brain. Sadly, this is often ‘written off’ in older folks who miss out on the care they need.

Haematologica 0109Here’s a paper published in the journal Haematologica that opens with…

Mild anemia is a frequent laboratory finding in the elderly usually disregarded in everyday practice as an innocent bystander.”

They took over three years to investigate the association of mild anemia with hospitalization and mortality in 7,536 subjects. Here’s what their data showed:

“The risk of hospitalization in the 3 years following recruitment was higher among the mildly anemic…Mortality risk in the following 3.5 years was also higher among the mildly anemic elderly…Similar results were found when slightly elevating the lower limit of normal hemoglobin concentration to 12.2 g/dL in women and to 13.2 g/dL in men.”

They conclude with this statement:

“After controlling for many potential confounders, mild grade anemia was found to be prospectively associated with clinically relevant outcomes such as increased risk of hospitalization and all-cause mortality.”

MedicineA study published not long ago in the journal Medicine also highlights the fact that even borderline anemia can have a big effect. First they note:

“The occurrence of anemia in older adults has been associated with adverse outcomes including functional decline, disability, morbidity, and mortality.”

In their study…

“Anemia was defined as hemoglobin <13 g/dL for men or <12g/dL for women.”

These levels are almost always ignored by most doctors. Here’s what their data showed:

“Anemia was associated with greater fatigue, lower handgrip strength, increased number of disabilities, and more depressive symptoms. Multivariate regression analysis…demonstrated strong associations for reduced hemoglobin, even within the “normal” range, and poorer health-related quality of life across multiple domains.”

Leading to the conclusion:

“Thus, anemia was independently associated with clinically significant impairments…Mildly low hemoglobin levels, even when above the World Health Organization (WHO) anemia threshold, were associated with significant declines in quality of life among the elderly.”

Current Opinion in HematologyAnother paper published in Current Opinion in Hematology begins with the familiar observation:

Anemia is common in older adults and is an independent predictor for increased morbidity and mortality in several disease states. Older persons with anemia suffer hospitalization, physical decline, and disability at higher rates than those people without anemia.”

In their study they found that a third of the cases were due to nutritional deficiencies (!), a third from chronic disease, and a third were unexplained (more on that in a future post). They too found that it predicted diminished physical performance and mobility, and reported the same finding that clarifies how we should understand ‘low’:

“The data suggest that the risk of mortality and loss of mobility even extends to levels of hemoglobin normally considered low normal by WHO criteria….”

Practitioners take note of their parting comment:

“Anemia is a common modifiable predictor of poor medical outcome in older adults and, as such, should be actively managed.”

PLoS OneI’ll introduce one more paper published in the Public Library of Science (PLoS One) that focuses on the damage to cognition and mood caused by mild anemia. In this study mood (depression), cognition, attention, memory and quality of life were all quantified for 4,068 individuals. Here’s what their data showed:

“In univariate analyses, mild anemic elderly persons had significantly worse results on almost all cognitive, functional, mood, and QoL (Quality of Life) measures. In multivariable logistic regressions…mild anemia remained significantly associated with measures of selective attention and disease-specific QoL.”

As in other studies, when the reference range was narrowed to a more precise ‘functional’ level, the deleterious effect of mild anemia was clear:

“When the lower limit of normal hemoglobin concentration according to WHO criteria was raised to define anemia (+0.2 g/dL), differences between mild anemic and non anemic elderly persons tended to increase on almost every variable.”

Here’s the bottom line: mild anemia has a profoundly negative impact on every aspect of function and should be investigated diligently as to its cause and treated accordingly.

Bookmark and Share

How important is Vitamin D for autoimmune disease?

Tuesday, March 9th, 2010

Nature Reviews RheumatologyIt’s hard to overemphasize the importance. Consider this paper published in Nature Reviews Rheumatology in which the authors assert that the…

…immunoregulatory and anti-inflammatory properties” of vitamin D can be used for the “control of autoimmune diseases.”

They note that…

“…Epidemiological evidence indicates a significant association between vitamin D deficiency and an increased incidence of several autoimmune diseases,”

Which include…

“a variety…from rheumatoid arthritis to systemic lupus erythematosus, and possibly also multiple sclerosis, type 1 diabetes, inflammatory bowel diseases, and autoimmune prostatitis.”

(Extra highlight for autoimmune prostatitis because very few are aware how common this is.) Of great practical importance is their observation that…

“The net effect of the vitamin D system on the immune response is an enhancement of innate immunity coupled with multifaceted regulation of adaptive immunity.”

PsychoneuroendocrinologyWe are awash in studies on vitamin D, here’s one more for good measure. This paper, recently published in the journal Psychoneuroendocrinology, focuses on its use in the treatment of autoimmune disease that attacks the brain and nervous system. The authors begin by noting that…

“It has been known for more than 20 years that vitamin D exerts marked effects on immune and neural cells…it has been shown that diminished levels of vitamin D…is a risk factor for various brain diseases.”

They further state that…

“…vitamin D has been found to be a strong candidate risk-modifying factor for Multiple Sclerosis (MS)…”

And proceed to..

“…assess how vitamin D imbalance may lay the foundation for a range of adult disorders, including brain pathologies (Parkinson’s disease, epilepsy, depression) and immune-mediated disorders (rheumatoid arthritis, type I diabetes mellitus, systemic lupus erythematosus or inflammatory bowel diseases).”

These are some of the reasons why I always screen for vitamin D sufficiency.

Bookmark and Share

How well can you smell: autoimmunity & neuropsychiatric disorders

Sunday, February 28th, 2010

Clinical ImmunologyThere is a connection between how well you can smell, brain damage from autoimmune inflammation, and psychiatric disease. Consider this fascinating paper published in the journal Clinical Immunology in which the authors discuss the inter-relationship between olfactory impairment, autoimmunity and neurological/psychiatric symptoms in several diseases affecting the central nervous system (CNS) such as Parkinson, Alzheimer’s disease, autism, schizophrenia, multiple sclerosis and neuropsychiatric lupus erythematosus. We suggest that common manifestations are not mere coincidences. Current data from animal models show that neuropsychiatric manifestations are intimately associated with smell impairment, and autoimmune dysregulation, via autoantibodies…”

Autoimmunity ReviewsIn another paper published in the journal Autoimmunity Reviews the authors note that “Research in the field of immunology as well as in various brain illnesses is beginning to indicate the increasing relevance of smell in pathophysiology.” They further state “…evidence exists that there may be something unique about the olfactory system that is inextricably related to immunological function. In addition, accumulating evidence confirms the existence of olfactory dysfunction in brain disease, much of which appears at early stages including multiple sclerosis, Alzheimer’s Disease, Parkinson’s Disease, schizophrenia and depression…under certain circumstances, olfactory abnormalities may be associated with autoimmune conditions. Since the organization of the olfactory system is so sensitive, impairment may be noted at an early stage. This may become important in the prediction of certain brain illnesses.”

International Journal of NeuroscienceThis paper recently published in the International Journal of Neuroscience focuses specifically on the link between olfaction, autoimmunity and Parkinson’s Disease. They first describe “the immune alterations observed in PD patients…the increase in the innate immune components including complement and cytokines within their substantia nigra and cerebrospinal fluid (CSF). These alterations extended to the adaptive immune response with the elevation of T cells and autoantibodies…in the peripheral blood and CSF of PD patients.” (Just the kinds of things we test for in the functional medicine approach.) They then describe the link between PD, autoimmunity and olfaction: Smell deficit is one of the earliest signs of PD and a unique observation suggesting olfactory declines to be a consequence of autoimmune mechanisms.”

AutoimmunityAnd the authors of this study published recently in the journal Autoimmunity observe that Psychiatric diseases are often associated with mild alterations in immune functions (e.g., schizophrenia) as well as autoimmune features. Recent evidence suggests that autoimmune diseases (AD) demonstrate a higher prevalence of psychiatric disorders, such as depression and psychosis, than in the normal population. Patients with AD often have an olfactory impairment as well, based on smell studies… ” They report that olfactory gene receptors have brain functions in addition to smell, and go on to describe the genetic polymorphisms (variations) that link autoimmunity, psychiatric disorders and smell impairment.

Israel Medical Association JournalThe paper that concludes this post is tantalizingly entitled Olfaction—A Window to the Mind. Published not long ago in The Israel Medical Association Journal, it is available here in its entirety. The authors comment that “The sense of smell can provide a natural window to the brain. This window provides an opportunity to examine neural mechanisms and brain function in a non-invasive way.” They then undertake a fascinating review of the field of olfactory studies encompassing aspects ranging from autoimmunity and neuropsychiatric disease to sexual function, addiction, social behavior and the discrimination of self from non-self. Their conclusion is worth bearing in mind: “…assessment of the sense of smell and olfactory impairments is usually overlooked by patients and their clinicians. Given the clinical data reviewed here, clinicians should be encouraged to screen for olfactory impairments, which can help in the early diagnosis of CNS diseases such as Parkinson, dementia and schizophrenia, as well as CNS-autoimmune diseases such as neuropsychiatric lupus.”

Bookmark and Share